News summaryADMA Biologics Investor RelationsNov 4, 2026, 12:00 PM
ADMA reports Q3 2026 results; raises adjusted earnings outlook
On Nov. 4, ADMA reported Q3 revenue of $141.1M (+5% YoY), ASCENIV revenue of $124.7M (+31%), GAAP net income of $49.9M (+37%) and gross margin of 71%; BIVIGAM revenue fell to $15.4M from $23.8M. It maintained FY2026 revenue guidance of at least $530M and raised adjusted net income and EBITDA outlooks to at least $180M and $275M.